엔버릭 바이오사이언시즈(ENVB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.62 (+1.89%), 시가총액 $0.00B, 52주 최저~최고 $0.58 ~ $10.33.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
엔버릭 바이오사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
엔버릭 바이오사이언시즈의 현재 주가는 $1.62 (+1.89%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
엔버릭 바이오사이언시즈의 시가총액은 약 $0.00B입니다.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the